Meg TirrellOvjeren akaunt

@megtirrell

Biotech and pharma reporter for

New York
Vrijeme pridruživanja: lipanj 2009.

Medijski sadržaj

  1. 28. sij

    Live look at ⁦⁩ tweeting about his upcoming appearance on ⁦

  2. 13. sij
  3. 7. sij

    What are journalists’ favorite snack food?

  4. 3. sij

    When I ordered a large I did not expect to be supplied with a week’s worth of iced coffee

  5. A brief holiday visit before the big show in two weeks. Hard to believe it’s the same city!

  6. Tearing up and cheering on as he announces his next chapter. We will miss you Bill - but so happy you’ll still be a anchor at large!

  7. Silently deflating your kid’s wilted birthday balloons while he naps: adulting

  8. Anyone not in biotech flying from San Diego to Orlando today must be wondering why they're surrounded by people in Patagonia vests talking about p-values -->

  9. When Cantor Fitzgerald’s Alethia Young comes to visit

  10. “The bottom line is, the FDA standard of approval is substantial evidence of efficacy and the cumulative data for aducanumab falls really far short of this standard to anyone but the most ardent GOOP subscribers.” <—⁦ note

  11. Odgovor korisnicima i sljedećem broju korisnika:
  12. Like drinking a gingerbread cookie. A caffeinated gingerbread cookie 😋

  13. Chief Medical Officer Al Sandrock on Alzheimer’s drug aducanumab. After the original futility analysis, he says, “we felt we had let down a lot of patients.”

    Prikaži ovu nit
  14. “Human intelligence is what really excites me,” ⁦⁩ says at , in discussion on power of patient advocates

  15. The twist: these coffees are iced! W ⁦

  16. Yes, yes I did make a 💩 joke (a couple actually) onstage at Harvard Medical School. And apparently I will still be invited back! ✅

  17. Could FDA employ blockchain to enable people to use their phones at the grocery store to see where their peaches have been from farm to table? ⁦⁩ talking about modernizing the regulator w ⁦

  18. “I think the industry’s earned it,” CEO Nick Leschly says of biopharma’s bad reputation. “There is egregious profit-taking by the industry, in some cases.” Calls out top 10 biologic drugs drawing hundreds of billions of $. “Why are we fighting biosimilars?”

    Prikaži ovu nit

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·